Acute Myeloid Leukemia

What is acute myeloid leukemia?

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. The bone marrow is the soft, spongy tissue inside bones where blood cells are made. In AML, the bone marrow produces large numbers of abnormal, immature white blood cells called myeloblasts, or “blasts.” These abnormal cells do not mature into healthy blood cells, and they multiply quickly, crowding out the normal cells the body needs: red blood cells that carry oxygen, platelets that help blood clot, and healthy white blood cells that fight infection.

The word “acute” means the disease usually develops and progresses quickly, often over days or weeks, rather than months or years. “Myeloid” refers to the family of blood cells affected — the line of cells that normally becomes red blood cells, platelets, and certain white blood cells. This distinguishes AML from lymphocytic (or lymphoblastic) leukemias, which affect a different family of white blood cells.

If you are searching for what is acute myeloid leukemia and who it affects, the short answer is that it can occur at any age, but it is most common in older adults, with risk increasing after around age 60. It also occurs in children, although childhood AML is less common than childhood acute lymphoblastic leukemia. AML affects men slightly more often than women. Because acute myeloid leukemia progresses rapidly, prompt diagnosis and treatment are important.

Symptoms of acute myeloid leukemia

Acute myeloid leukemia symptoms are usually caused by the shortage of normal blood cells rather than by the leukemia cells themselves. Because red cells, platelets, and healthy white cells are all reduced, symptoms often appear in several body systems at once. Many people describe feeling unwell for only a few weeks before diagnosis, reflecting how quickly the disease develops.

Common acute myeloid leukemia symptoms include:

• Fatigue and weakness — often caused by anemia, a shortage of red blood cells.
• Shortness of breath, especially with activity, also related to anemia.
• Pale skin compared to the person’s usual complexion.
• Frequent or persistent infections, such as recurring fevers, sore throats, or infections that are slow to heal, because healthy infection-fighting white cells are reduced.
• Fever without an obvious infection.
• Easy bruising or bleeding — nosebleeds, bleeding gums, heavy menstrual periods, or bruises that appear without a clear cause, due to low platelets.
• Petechiae — tiny, flat red or purple spots on the skin caused by small bleeds under the skin.
• Bone or joint pain, from leukemia cells building up inside the bone marrow.
• Unintended weight loss and loss of appetite.
• Swollen gums or, less often, painless lumps under the skin, which can occur when leukemia cells collect in tissues (this is seen in certain subtypes of AML).

Unlike many solid tumors, AML is not usually described in numbered “stages,” because it is a disease of the blood and marrow that is spread throughout the body from the start. Instead, doctors classify AML into subtypes based on the appearance and genetic features of the leukemia cells. Symptoms can differ somewhat by subtype. For example, one subtype, acute promyelocytic leukemia (APL), is particularly associated with serious bleeding and clotting problems and is treated as a medical emergency. In some people, AML develops from an earlier bone marrow condition such as myelodysplastic syndrome, and symptoms such as fatigue may have been present in a milder form for months before the leukemia declared itself.

None of these symptoms is specific to leukemia — most are far more often caused by common, less serious conditions. However, when several occur together or worsen quickly, medical evaluation is important.

Causes and risk factors

Acute myeloid leukemia causes are not fully understood. AML develops when the DNA (the genetic instructions) inside a developing blood cell in the bone marrow acquires mutations — changes that make the cell grow and divide uncontrollably and stop it from maturing normally. In most people, doctors cannot identify a specific cause for these mutations, and in the majority of cases the disease appears without any known trigger.

Several factors are known to increase the risk of developing AML:

• Older age. AML becomes more common with advancing age, particularly after 60.
• Previous cancer treatment. Certain chemotherapy drugs and radiation therapy given for another cancer can increase the risk of developing AML years later. This is sometimes called therapy-related AML.
• Exposure to high doses of radiation, such as from nuclear accidents.
• Long-term exposure to certain chemicals, most notably benzene, an industrial chemical found in some workplaces and in tobacco smoke.
• Smoking. Cigarette smoke contains benzene and other cancer-causing substances and is a recognized risk factor for AML.
• Other blood disorders. Conditions such as myelodysplastic syndrome, myeloproliferative disorders, or aplastic anemia can sometimes transform into AML over time.
• Genetic conditions. Some inherited syndromes, including Down syndrome, Fanconi anemia, and certain other rare disorders, are associated with a higher risk of AML, particularly in children.
• Family history. Most cases of AML are not inherited, but in a small number of families an inherited predisposition to blood cancers is present.

It is important to understand that having one or more risk factors does not mean a person will develop AML, and many people diagnosed with acute myeloid leukemia have no identifiable risk factor at all. AML is not contagious and cannot be passed from person to person.

Diagnosis

Acute myeloid leukemia diagnosis begins with a careful medical history and physical examination, but the condition can only be confirmed with laboratory testing of the blood and bone marrow. Doctors typically use the following tests:

• Complete blood count (CBC). This common blood test measures the numbers of red cells, white cells, and platelets. In AML, the results are often abnormal — for example, low red cells and platelets, and a white cell count that may be high, low, or normal. A blood smear, in which a drop of blood is examined under a microscope, may show immature blast cells.
• Bone marrow aspiration and biopsy. This is the key test for confirming AML. A doctor uses a needle, usually inserted into the back of the hip bone under local anesthesia, to remove a small sample of liquid marrow (aspiration) and a tiny core of bone and marrow tissue (biopsy). Specialists then examine the cells under a microscope. In general, a diagnosis of AML is made when at least 20 percent of the cells in the marrow or blood are myeloid blasts, or when certain specific genetic abnormalities are found.
• Immunophenotyping (flow cytometry). This laboratory technique identifies proteins on the surface of the leukemia cells, confirming that they belong to the myeloid family and helping to define the exact subtype.
• Cytogenetic and molecular genetic testing. These tests look for chromosome changes and gene mutations inside the leukemia cells. The results are essential in modern care because they help predict how the disease is likely to behave and guide the choice of treatment, including whether targeted drugs may be appropriate.
• Lumbar puncture (spinal tap). In selected cases — for example, when there are neurological symptoms — doctors may sample the fluid around the spinal cord to check whether leukemia cells have spread there. This is not routine for every patient.
• Imaging tests. Imaging is not used to diagnose AML itself, but chest X-rays, ultrasound, CT scans, or in some situations PET-CT imaging may be used to check for infections, assess organs, or investigate collections of leukemia cells outside the marrow.

Additional tests, such as heart and kidney function checks, are usually performed before treatment begins to make sure the planned therapy is as safe as possible.

Treatment options

Acute myeloid leukemia treatment usually needs to start soon after diagnosis, because the disease progresses quickly. The treatment plan depends on the AML subtype, the genetic features of the leukemia cells, the patient’s age and overall health, and personal preferences. In many hospital groups, including Acibadem, care is coordinated through a specialized medical oncology department working together with hematology (blood disorder) specialists.

Chemotherapy

Chemotherapy — medication that kills rapidly dividing cells — is the foundation of acute myeloid leukemia treatment for most patients. It is typically given in phases:

• Induction therapy. The first, intensive phase aims to achieve remission, meaning no leukemia cells can be detected in the blood or marrow by standard tests and normal blood cell production recovers. This usually requires a hospital stay of several weeks because blood counts fall sharply before recovering.
• Consolidation (post-remission) therapy. Even when remission is achieved, some leukemia cells may remain. Further cycles of chemotherapy are given to reduce the risk of the disease returning.

Targeted therapy

For some patients, the genetic testing done at diagnosis identifies specific mutations that can be treated with targeted drugs — medicines designed to block particular abnormal proteins in the leukemia cells. These may be given together with chemotherapy or, in some cases, on their own. Whether targeted therapy is an option depends entirely on the genetic profile of the individual leukemia.

Lower-intensity treatment

Intensive chemotherapy is not suitable for everyone. Older patients or those with other serious health conditions may be offered lower-intensity treatments, such as gentler chemotherapy drugs, often combined with newer targeted medicines. These regimens aim to control the disease while limiting side effects. Your doctor may discuss the balance between treatment intensity and quality of life in detail.

Stem cell transplantation

A stem cell transplant (also called a bone marrow transplant) may be recommended for patients whose AML has a higher risk of returning, or whose disease has relapsed. In the most common form, called an allogeneic transplant, high-dose chemotherapy is followed by an infusion of healthy blood-forming stem cells from a donor. The transplant can offer the possibility of long-term disease control, but it carries significant risks and is not appropriate for every patient. Comprehensive leukemia and lymphoma treatment programs typically include transplant evaluation as part of the overall care pathway.

Treatment of acute promyelocytic leukemia

The APL subtype is treated differently, using medicines such as all-trans retinoic acid (a vitamin A–derived drug) and arsenic trioxide, which cause the abnormal cells to mature. With modern therapy, this subtype often responds very well, which is one reason accurate subtyping at diagnosis matters so much.

Treatment in children

Children with AML are treated with protocols adapted to their age and physiology, usually within dedicated pediatric oncology services, where teams are experienced in supporting both the child and the family throughout treatment.

Supportive care and other approaches

Supportive care is an essential part of AML treatment. It includes transfusions of red cells and platelets, antibiotics and antifungal medicines to prevent and treat infections, and medicines to manage side effects such as nausea. Surgery plays no meaningful role in treating AML itself, since the disease is spread through the blood and marrow. Watchful waiting is generally not appropriate for AML because the disease progresses rapidly; however, for some very frail patients, care may focus entirely on comfort and symptom control rather than anti-leukemia therapy. Clinical trials — carefully supervised studies of new treatments — may also be an option, and patients can ask their care team whether any are available and suitable.

Living with acute myeloid leukemia / outlook

A diagnosis of acute myeloid leukemia is life-changing, and it is natural to have questions about the future. Outcomes vary widely from person to person. Factors that influence prognosis include the genetic features of the leukemia cells, the patient’s age and general health, whether the AML developed after previous cancer treatment or another blood disorder, and how the disease responds to initial therapy. Younger patients and those with favorable genetic profiles often do better, and some subtypes, such as APL, tend to respond particularly well to modern treatment. In many cases, remission can be achieved, and a proportion of patients remain free of disease long term; in others, the leukemia may return and require further treatment.

During and after treatment, regular follow-up with blood tests and sometimes bone marrow examinations is standard, so that any sign of relapse can be found early. Living with AML also involves practical adjustments: protecting yourself from infection while blood counts are low, eating as well as possible, managing fatigue by pacing activities, and paying attention to emotional health. Anxiety and low mood are common and understandable; counseling, support groups, and open conversations with the care team can help. Family members and caregivers often benefit from support as well.

Honest, ongoing conversations with your hematology and oncology team are the best way to understand what the outlook means in your individual situation, because general statistics cannot predict any one person’s course.

Frequently asked questions

What is acute myeloid leukemia in simple terms?

Acute myeloid leukemia is a fast-growing cancer of the blood and bone marrow. The marrow produces abnormal, immature white blood cells that multiply quickly and crowd out healthy blood cells. This leads to symptoms such as fatigue, infections, and easy bleeding, and it requires prompt medical treatment.

Can acute myeloid leukemia be cured?

In some patients, yes — long-term remission with no return of the disease is possible, particularly in younger patients, in those with favorable genetic features, and in certain subtypes such as acute promyelocytic leukemia. However, outcomes vary considerably, and no doctor can guarantee a cure. Treatment aims first to achieve remission and then to prevent relapse, sometimes with a stem cell transplant. Your care team can explain what is realistic in your specific case.

How serious is acute myeloid leukemia?

AML is a serious condition that usually progresses quickly without treatment, which is why therapy typically begins soon after diagnosis. That said, it is also a treatable disease, and many patients achieve remission with modern therapy. Seriousness depends on individual factors, including the genetic subtype, age, overall health, and response to initial treatment.

What are the first signs of acute myeloid leukemia?

Early acute myeloid leukemia symptoms are often vague and flu-like: tiredness, fever, and frequent infections. Easy bruising, bleeding gums, tiny red skin spots, paleness, shortness of breath, and bone pain are also common early signs. Because these symptoms overlap with many minor illnesses, a blood test is usually what first raises suspicion of leukemia.

How is acute myeloid leukemia diagnosed?

Diagnosis starts with blood tests, including a complete blood count and a blood smear. Confirmation requires a bone marrow aspiration and biopsy, in which a small sample of marrow is examined under a microscope and analyzed with specialized laboratory tests. Genetic testing of the leukemia cells is also standard, because it guides treatment decisions and helps predict the likely course of the disease.

How long does treatment and recovery take?

Intensive treatment usually involves several weeks in the hospital for induction chemotherapy, followed by additional cycles of consolidation therapy over the following months. If a stem cell transplant is needed, recovery can take many months longer. Timelines vary widely depending on the treatment chosen, complications, and how the disease responds, so your care team is the best source of a realistic estimate for your situation.

Can children get acute myeloid leukemia?

Yes. Although AML is more common in older adults, it also occurs in children and adolescents. Childhood AML is treated with protocols designed specifically for young patients, delivered by pediatric oncology teams. Children with certain genetic conditions, such as Down syndrome, have a higher risk, but most children who develop AML have no known risk factor.

When to see a doctor

See a doctor promptly if you have persistent, unexplained symptoms such as ongoing fatigue, recurring infections, unusual bruising or bleeding, night sweats, or unintended weight loss. Most people with these symptoms will not have leukemia, but they deserve proper evaluation, and a simple blood test can often provide answers quickly.

Seek urgent medical care — going to an emergency department if necessary — if you or someone you care for experiences any of the following red-flag warning signs, especially if already diagnosed with or being treated for acute myeloid leukemia:

• Fever of 38°C (100.4°F) or higher, particularly during or after chemotherapy, when infections can become dangerous very quickly.
• Bleeding that will not stop, such as prolonged nosebleeds, blood in the urine or stool, or vomiting blood.
• A sudden rash of tiny red or purple spots (petechiae) or rapidly spreading bruises.
• Severe shortness of breath, chest pain, or a racing heartbeat.
• Severe headache, confusion, drowsiness, vision changes, or weakness on one side of the body, which could indicate bleeding or other complications affecting the brain.
• Signs of serious infection, such as shaking chills, difficulty breathing, or feeling faint or very unwell.
• Extreme paleness with dizziness or fainting.

Acting quickly on these warning signs can be lifesaving. If you are already under treatment for AML, follow the emergency instructions your care team has given you and let them know about any new or worsening symptoms without delay.